Hello, Thanks for signing up for MarketBeat Daily Ratings—we’re excited to have you on board. Every weekday, you’ll get a curated summary of new “Buy” and “Sell” ratings from Wall Street’s top-rated analysts, the latest stock news, and bonus investing content—all delivered straight to your inbox. You’re just two quick steps away from completing your sign-up: 1. Make sure our emails go to your inboxGmail users:
Mobile: Tap the three dots (…) in the top right and select Move to Inbox or Move to Primary
Desktop: Click the folder icon at the top and select Move to Inbox or Primary Apple Mail users:
Tap our email address at the top (next to From: on mobile), then select Add to VIP Other providers:
Reply to this message and add newsletters@analystratings.net to your contacts 2. Confirm your subscriptionClick this link to confirm your subscription. This verifies your account and ensures you receive your newsletters without interruption instead of getting stuck in your spam filter. Confirm your subscription here. After you confirm, feel free to download our popular free report, "7 Stocks to Buy and Hold Forever" with this link. Thanks again for subscribing—we look forward to being part of your investing journey. 
Matthew Paulson
Founder and CEO, MarketBeat. P.S. If you didn’t mean to subscribe, no problem—you can unsubscribe here.
Exclusive Article from MarketBeat.com
A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?By Jeffrey Neal Johnson. Date Posted: 4/7/2026. 
Key Points
- Abbott's Medical Devices division continues to accelerate, demonstrating the underlying strength within the company's largest business segment.
- Abbott's impressive history of consecutive dividend increases underscores its commitment to consistently rewarding long-term shareholders.
- Strategic acquisitions are positioning Abbott to lead in new high-growth healthcare sectors, securing a powerful pipeline for future expansion.
- Special Report: Have $500? Invest in Elon’s AI Masterplan
In the world of investing, stability is a prized commodity. Few companies embody that stability better than Abbott Laboratories (NYSE: ABT), a diversified healthcare powerhouse and a member of the elite dividend kings. For decades, investors have relied on Abbott for steady growth and dependable income. That long-standing reputation makes its recent performance all the more striking.
In the next 3 minutes…
James Altucher – legendary investor and venture capitalist…
And someone who’s known for playing his cards “close to the vest”…
Is going to give you the name and ticker symbol of a company he believes will skyrocket thanks to the coming Starlink IPO… Click here to watch this short 3-minute video now.
Abbott Laboratories’ stock price recently touched its 52-week low, closing just above $100 in the last trading days of March. This sharp downturn has left many wondering whether the foundation of this industry leader is cracking. A closer look at Abbott’s situation suggests a disconnect between market sentiment and operational reality. That raises a key question: Is the market’s pessimism justified, or has a value opportunity emerged for long-term investors? Separating the Signal From the NoiseA stock like Abbott doesn't fall without reason, and its recent decline stems from two distinct pressures. The first is an internal headwind in its Nutrition segment. Abbott Laboratories’ fourth-quarter 2025 earnings report showed a 9.1% organic sales decline in that division, primarily due to market-share losses in the U.S. pediatric business and pricing dynamics that constrained volume. Management has been transparent about the challenge and outlined a clear turnaround plan. CEO Robert B. Ford described price and promotion initiatives plus a pipeline of at least eight new product launches in 2026 aimed at restoring volume growth, with a projected recovery in the second half of the year. The second factor is broader and external. The market has been rotating capital away from defensive sectors like the healthcare sector toward higher-beta areas such as artificial intelligence (AI) and the energy sector in search of faster returns. That broad trend has pressured many fundamentally sound healthcare companies, including Abbott, for reasons largely unrelated to their individual performance or long-term prospects. Abbott’s Engine Room Is Running StrongWhile Nutrition works through a short-term recovery, Abbott’s core remains exceptionally strong, powered by its largest and most profitable division: Medical Devices. That segment is not just stable—it is accelerating, delivering 10.4% organic growth in the most recent quarter. Abbott’s diversified model provides a powerful counterbalance to the isolated weakness in Nutrition; the company’s true health is most evident in these high-performing areas.
Medical Devices: The Medical Devices engine is firing on multiple cylinders, driven by market-leading innovation in critical care areas. Diabetes Care: The FreeStyle Libre franchise of continuous glucose monitors (CGM) continues to be a growth phenomenon. This product line, which lets users track glucose without routine fingersticks, generated over $7.5 billion in sales in 2025 and remains a primary driver of Abbott's success. Cardiovascular Leadership: Abbott is also a dominant force in cardiovascular health. Its Electrophysiology business grew at a double-digit rate, while Structural Heart posted strong organic growth of 8.7%. This strength stems from best-in-class products—such as MitraClip and TriClip—that offer minimally invasive solutions for valve repair, and from a pipeline of innovations, including the recently FDA-approved Volt PFA System for treating atrial fibrillation. Abbott is also positioning for future growth through its planned acquisition of Exact Sciences. Exact Sciences is known for non-invasive cancer screening, notably the Cologuard test, and will add a high-growth diagnostics vertical to Abbott’s portfolio. The deal would immediately expand Abbott’s presence in the rapidly growing market for cancer diagnostics, creating a new revenue stream with multi-year upside potential. That outlook is shared by professional analysts. Wall Street currently assigns Abbott a Moderate Buy consensus, with an average 12-month price target of $135.47—implying more than 30% potential upside from recent levels and suggesting many believe the stock is undervalued. A Bedrock of Reliability for Income InvestorsFor long-term investors focused on reliable income, Abbott’s dividend is especially compelling. Abbott is a member of the S&P 500 Dividend Kings, an exclusive group of companies that have increased their dividend for at least 50 consecutive years. That track record demonstrates a deep commitment to returning capital to shareholders through all market cycles. The recent decline in Abbott’s stock price has a direct benefit for new investors: a higher dividend yield. At current prices, Abbott offers a yield of about 2.5%, allowing investors to lock in a stronger rate of income from a historically reliable payer. The dividend payout ratio is roughly 68% of earnings and only about 37% of cash flow, indicating Abbott generates more than enough cash to cover its dividend with room for future increases. A Disconnect Between Price and ValueCurrent market sentiment around Abbott appears disconnected from the company’s business fundamentals. Temporary headwinds in a single division and broader market rotation have depressed the stock price, yet Abbott’s core growth engines are accelerating. Its dominant Medical Devices division continues to deliver, the dividend remains a bedrock of reliability, and strategic catalysts such as the Exact Sciences acquisition could add substantial long-term growth. For investors with a multi-year perspective, the present valuation highlights a meaningful gap between market price and intrinsic value—an opportunity worth considering. |
